EZH2蛋白在食管癌组织中的表达

EXPRESSIONS OF THE EZH2 PROTEIN IN THE CARCINOMA OF ESOPHAGUS

目的观察EZH2蛋白在食管鳞癌和腺癌组织中的表达,探讨EZH2蛋白与侵袭、转移程度不同的食管鳞癌及不同病理分级、组织类型食管癌之间的关系。方法采用免疫组织化学染色法、免疫印迹法,分析检测食管癌标本中EZH2蛋白的表达。结果食管癌组织标本均高表达EZH2蛋白,阳性染色定位于细胞核;部分正常组织、癌旁组织也有弱阳性着色。免疫印迹分析表明,食管鳞癌组织EZH2蛋白的表达明显高于癌旁及正常黏膜组织(P<0.01)。癌旁组织高于正常黏膜组织(P<0.05)。浸润、转移性食管鳞癌EZH2蛋白表达明显上调,与未发生浸润、转移的相比,差异有显著性(P<0.05)。高分化鳞癌EZH2蛋白表达低于中、低分化者;但食管腺癌则相反,高分化腺癌的表达高于中、低分化者。结论EZH2蛋白在食管癌高表达,并与其组织类型、侵袭和转移特性密切相关。

Objective To investigate the expressions of enhancer of zeste （EZH2） in carcinoma of esophagus and its potential significance. Methods The expression and distribution of EZH2 were determined on the esophageal squamous carcinoma, adenocarcinoma by using immunohistochemistry. We then detected EZH2 protein expression in the esophageal squamous carcinoma, paracarcinomatous and normal tissues by Western blotting. Results The immunohistochemical staining showed EZH2 protein was highly expressed in esophageal squamous carcinoma and adenocarcinoma tissues. The positive staining was observed in the nuclear region. Normal tissues and corresponding paracarcinomatous tissues were stained weakly. Western blotting analysis showed that the strongest positive signals were detected in the esophageal squamous carcinoma （P 〈 0.01 ）. The positive signals were stronger in corresponding paracarcinomatous tissue than that in normal tissues （P 〈 0.05） The expression of EZH2 protein in invasive and metastatic carcinomas had strikingly increased, compared with carcinomas without invasion and metastases, which had significant differences in the statistics （ P 〈 0.05）. The expression of EZH2 in well differentation squamous carcinoma was significantly lower than that in medium or poor differentiation respectively. However, the expression in well differentation adenocarcinoma was significantly higher than that in medium or poor differentiation. Conclusion EZH2 protein was highly expressed in esophageal carcinoma. The expression of EZH2 protein was clearly associated with invasion, metastases and tissue types of esophageal carcinoma.